Physician profile
Brandt Esplin
NPI 1285929430
$4,314.91
in general payments reported to CMS, 2019-2025
39 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $26.84 · 2021: $139 · 2022: $722 · 2023: $795 · 2024: $1,162 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854 · Education: $30.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.09 |
| Education | $30.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $537.28 | 2019-2025 | |
| Fennec Pharmaceuticals, INC. | $341.28 | 2024 | Pedmark |
| Glaxosmithkline, LLC. | $280.56 | 2021-2025 | Zejula, Jemperli, Shingrix |
| Merck Sharp & Dohme LLC | $267.52 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $237.99 | 2020-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $231.55 | 2019-2025 | Opdualag, Opdivo |
| Astellas Pharma US INC | $216.02 | 2019-2024 | Padcev, Xtandi |
| Alexion Pharmaceuticals, INC. | $184.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $178.17 | 2022-2025 | |
| Abbvie INC. | $176.64 | 2022-2025 | |
| Array Biopharma INC | $166.68 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Celgene Corporation | $160.38 | 2022-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $155.15 | 2019-2024 | |
| Seagen INC. | $136.45 | 2022-2023 | Adcetris |
| Emd Serono, INC. | $126.51 | 2022-2024 | Bavencio |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $122.70 | 2021-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $113.94 | 2021-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $65.41 | 2020-2024 | |
| Janssen Biotech, INC. | $57.90 | 2019-2023 | Darzalex, Imbruvica |
| Geron Corporation | $51.66 | 2025 | Rytelo |
| Incyte Corporation | $47.41 | 2019-2025 | Jakafi |
| Amgen INC. | $43.78 | 2022-2023 | Lumakras |
| Genentech USA, INC. | $41.00 | 2022 | |
| Exelixis INC. | $32.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $31.97 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $30.48 | 2025 | Enjaymo |
| Sobi, INC | $29.42 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.70 | 2022 | |
| Daiichi Sankyo INC. | $27.19 | 2023 | Enhertu |
| Histosonics, INC. | $25.09 | 2025 | |
| Boston Scientific Corporation | $23.70 | 2022 | |
| Lilly USA, LLC | $23.47 | 2019 | |
| Genmab U.S., INC. | $22.42 | 2025 | Tivdak |
| Novocure INC. | $20.32 | 2025 | Optune Lua (Novottf-200t) |
| Puma Biotechnology, INC. | $19.43 | 2025 | |
| Eisai INC. | $15.69 | 2022 | |
| Morphosys, US INC. | $15.67 | 2023 | Monjuvi |
| Apellis Pharmaceuticals, INC. | $14.82 | 2022 | |
| Secura Bio, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandt Esplin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.